Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

WHAT'S NEW

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Sep 13 2019

Full Issue

Purdue Pharma Nixed Plans To Support Opioid-Addiction Treatment As Barrage Of Lawsuits Flooded In

Purdue Pharma and the Sackler family would have donated $50 million a piece to fund the foundation, but the idea got derailed when it began contemplating bankruptcy and working out court settlements with states. Meanwhile, historians are asking that any opioid settlements being worked out be made public so they can be preserved for the future. News on the crisis comes out of North Carolina as well.

The Wall Street Journal: Purdue Pharma Made, Then Ditched, Plans For Opioid-Treatment Nonprofit

OxyContin maker Purdue Pharma LP nixed plans earlier this year to launch a foundation to fund opioid-addiction treatment and research as the company rethought its strategy amid hundreds of lawsuits and a possible bankruptcy filing. Purdue staff pitched the foundation concept several years ago, and the drugmaker’s owners and executives spent several months developing the latest version, according to people familiar with the matter and internal company emails viewed by The Wall Street Journal. (Hopkins, 9/12)

PBS NewsHour: What A Purdue Settlement Would Mean For Fighting The Opioid Crisis

On Wednesday it was reported that the pharmaceutical company has reached a deal with nearly two dozen states and more than 2,000 cities and counties for a tentative settlement. Purdue Pharma would not confirm that settlement when asked by the PBS NewsHour. But the National Prescription Opioid Litigation group, which represents the cities and counties that sued drug companies over the opioid crisis, issued a statement on Wednesday saying the breakthrough was heartening. (Santhanam, 9/12)

The Associated Press: Chaotic Talks Show Challenge Of Reaching Opioid Settlement

For months, the judge overseeing national litigation over the opioids crisis urged all sides to reach a settlement that could end thousands of lawsuits filed by state and local governments. But the chaotic developments this week in the case against OxyContin maker Purdue Pharma underscore how difficult that goal is. By Thursday, half of the nation’s state attorneys general said they would reject a tentative deal crafted by the other half, and many criticized the terms as grossly insufficient. (Mulvihill, 9/13)

Stat: Historians Seek Public Archive Of Documents From Opioid Litigation

In settling lawsuits against them, companies often insist that all of the documents and depositions gathered as part of the cases be locked away or destroyed. To head that off — and to ensure a full accounting of the origins of the prescription opioid crisis — a group of historians is asking that any settlement in the massive opioid litigation require all collected documents be preserved and made public. In a court brief Thursday, the experts called for “full and permanent access to the records” for scholars, policymakers, journalists, and the public, and for the defendants to cover the costs of creating an archive. (Joseph, 9/12)

Colorado Sun: Colorado Isn’t Part Of Settlement With Opioid Maker Purdue Pharma; Attorney General Calls Offer “Inadequate”

Colorado is not part of a tentative national settlement with opioid maker Purdue Pharma, Attorney General Phil Weiser said Wednesday. Weiser says the up to $12 billion deal reached between many other states and thousands of local governments isn’t adequate to address the company’s impacts in Colorado. (Paul and Ingold, 9/11)

North Carolina Health News: N.C. Efforts To Reduce Opioid Dependency Highlighted In National Report

In a national report subtitled “Leading-edge Practices and Next Steps,” the American Medical Association and consulting firm Manatt Health highlighted a North Carolina Medical Society initiative to support providers treating opioid use disorder. Project OBOT, short for office-based opioid treatment, helps North Carolina providers get trained to prescribe medication-assisted treatment (MAT) to patients and eases roadblocks for patients beginning and staying on MAT. (Duong, 9/13)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 6
  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF